Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山医筠集团股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(formerly known as Guangzhou Pharmaceutical Company Limited (廣州藥業股份有限公司))
(H Share Stock Code: 0874)

ANNOUNCEMENT OF RESOLUTIONS PASSED AT THE 25th MEETING OF THE FIFTH SESSION OF THE BOARD

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on the The Stock Exchange of Hong Kong Limited.

The 25th meeting of the fifth session of the board of directors (the "Board") of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (廣州白雲山醫藥集團股份有限公司) (formerly known as Guangzhou Pharmaceutical Company Limited (廣州藥業股份有限公司)) (the "Company") was held on 23 August 2013 by means of communication voting, notice of which was despatched on 20 August 2013 by way of fax and email. All of the eight eligible directors attended the meeting. The meeting was convened and held in compliance with the requirements of the Company Law and the Articles of Association of the Company.

All of the following resolutions were passed with 8 affirmative votes, no dissenting and abstaining vote.

- 1. The resolution on the change of the stock short name of the Company.
- 2. The resolution on the change of the logo of the Company.

The Board of

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 23 August 2013

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Ms. Cheng Ning and Mr. Wu Changhai as executive directors, and Mr. Liu Jinxiang, Mr. Li Shanmin, Mr. Zhang Yonghua, Mr. Wong Lung Tak Patrick and Mr. Qiu Hongzhong as independent non-executive directors.